Table of Contents
Journal of Allergy
Volume 2012, Article ID 253879, 6 pages
http://dx.doi.org/10.1155/2012/253879
Research Article

Quality of Life Improvement with Sublingual Immunotherapy: A Prospective Study of Efficacy

1Allergy Associates of La Crosse and Mayo Clinic Health System Franciscan Healthcare-La Crosse-Onalaska, WI 54650, USA
2Allergychoices Inc., Onalaska, WI 54650, USA
3College of Science and Health, University of Wisconsin-La Crosse, La Crosse, WI 54601, USA
4Allergy and Asthma Center, Hagerstown, MD 21740, USA

Received 29 September 2011; Revised 23 November 2011; Accepted 24 November 2011

Academic Editor: Nazan Cobanoglu

Copyright © 2012 Mary S. Morris et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Due to its excellent safety profile, ease of administration, and economic considerations, sublingual immunotherapy (SLIT) is becoming a preferred form of allergen specific immunotherapy. The efficacy of SLIT is still debated. The purpose of this act of practice trial is to evaluate quality of life outcomes in patients treated with SLIT. Fifty one patients with allergic rhinoconjunctivitis demonstrated by skin testing completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation, at four months and at 10–12 months of SLIT. Significant improvement ( 𝑃 < 0 . 0 5 ) on six of seven domain categories of the RQLQ questionnaire was noted. Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.